Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

IRB Fills Trafalgar Gap

By Drug Discovery Trends Editor | July 18, 2012

In the wake of news that Trafalgar Ethics Board Inc. suddenly ceased operations last month, Institutional Review Board Services has quickly stepped in to ensure a smooth transition, bringing peace of mind to both researchers and participants currently involved in important clinical studies across the country.

“This is one of the very few first times in North America that an independent ethics board has had to voluntarily close its doors,” said IRB Services president Jack Corman, noting that it was extremely important to ensure ongoing ethical oversight for all research studies and clinical trials engaged by TEB. “Otherwise, there would be no ethics approval in place for the research which is a very serious breach of Canadian, U.S. and international clinical trial regulations and all research activity would have had to cease,” he added.

Founded in 1993, IRB Services is an independent organization accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) and dedicated to protecting the rights and safety of human subjects. IRB Services operates research ethics committees in Toronto, Ontario; Montreal, Quebec; and Boca Raton, Florida, which review a wide range of both industry and publicly funded human subject research across multiple disciplines, including Health Canada, Food and Drug Administration, and US Department of Health and Human Services regulated research.

Trafalgar Ethics Board, based in Oakville, Ontario, chose IRB Services to help guide the shutting down process, relying on IRB Services’ strong reputation as the leading Canadian independent board to ensure continuity of ethics approval for vital research. Since June, IRB Services has assumed responsibility for the majority of TEB research projects, conducting thorough re-reviews and issuing re-approvals of nearly 40 studies involving approximately 200 researchers in just 17 business days. The acquired projects include urology, allergy and behavioural studies involving top pharmaceutical companies as well as independent research organizations.

“We successfully chartered new territory for the industry, demonstrating a viable course of action for board closure that established continued ethical oversight as well as continued protection for study participants,” noted Corman. “Our thorough re-review process minimized any lapse in ethical approval and gave researchers the confidence to continue to recruit new patients for their studies.”

The transition process set out by IRB Services closely mirrors draft guidance recently announced by the Federal Drug Administration (FDA) and Office for Human Rights Protection (OHRP) in the U.S. entitled: Considerations in Transferring a Previously-Approved Research Project to a New IRB or Research Institution. “The similarity between our approach and the joint guidance put forth by the FDA and OHRP demonstrates its validity,” said Corman.

Last year, IRB Services became the first fully independent, unaffiliated Canadian-based research ethics committee to earn accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The company strongly advocates that ethical review and approval should be kept at an arm’s length from the research organizations and companies who conduct and sponsor research. It is also actively involved in assisting Health Canada to develop standards for Canadian ethics boards and is the only independent review board to be officially recognized by the province of Saskatchewan.

Date: July 2, 2012
Source: Institutional Review Board Services


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE